Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of sugammadex in kidney transplant recipients
ChiCTR2400081701Phase 4Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Mar 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex in end-stage kidney disease (ESKD) and kidney transplant (2 arms), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Patient survival at 1, 3, and 5 years postoperatively, Death-censored graft survival at 1, 3, and 5 years postoperatively and 1 more. Started Mar 2024; status: completed.
02
Drugs
Sugammadex
03
Conditions
end-stage kidney disease (ESKD)kidney transplant
Beyond the preview
Go deeper on ChiCTR2400081701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081701.